PT2846770T - Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas - Google Patents
Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicasInfo
- Publication number
- PT2846770T PT2846770T PT13730352T PT13730352T PT2846770T PT 2846770 T PT2846770 T PT 2846770T PT 13730352 T PT13730352 T PT 13730352T PT 13730352 T PT13730352 T PT 13730352T PT 2846770 T PT2846770 T PT 2846770T
- Authority
- PT
- Portugal
- Prior art keywords
- neurooncologic
- neuroinflammatory
- neurodegenerative
- therapy
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000814A ITMI20120814A1 (it) | 2012-05-11 | 2012-05-11 | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2846770T true PT2846770T (pt) | 2018-10-15 |
Family
ID=46582908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT13730352T PT2846770T (pt) | 2012-05-11 | 2013-05-10 | Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150132397A1 (pt) |
EP (1) | EP2846770B1 (pt) |
CN (1) | CN104427975A (pt) |
DK (1) | DK2846770T3 (pt) |
ES (1) | ES2686561T3 (pt) |
IN (1) | IN2014MN02475A (pt) |
IT (1) | ITMI20120814A1 (pt) |
PL (1) | PL2846770T3 (pt) |
PT (1) | PT2846770T (pt) |
WO (1) | WO2013168131A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104490873A (zh) * | 2014-11-25 | 2015-04-08 | 邹丽萍 | 一种治疗儿童结节性硬化症的药物 |
GB2564383B (en) * | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
CN109406650A (zh) * | 2018-10-25 | 2019-03-01 | 美康生物科技股份有限公司 | 用于准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法 |
CN109187839A (zh) * | 2018-10-25 | 2019-01-11 | 美康生物科技股份有限公司 | 准确测定人全血中四种免疫抑制剂类药物浓度的试剂盒及检测方法 |
IT202000007228A1 (it) * | 2020-04-06 | 2021-10-06 | Diego Dolcetta | SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE |
KR20230037647A (ko) * | 2020-07-14 | 2023-03-16 | 얀센 파마슈티카 엔.브이. | 타우병증 또는 아밀로이드성 질환을 검출하기 위한 혈액-기반 검정 |
TW202233666A (zh) * | 2020-10-26 | 2022-09-01 | 比利時商健生藥品公司 | 減少人類對象中之tau的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003272539A1 (en) * | 2002-09-17 | 2004-04-08 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
ATE520400T1 (de) * | 2002-11-21 | 2011-09-15 | Genzyme Corp | Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung |
US20080207671A1 (en) * | 2006-07-31 | 2008-08-28 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
US20090274764A1 (en) * | 2008-04-30 | 2009-11-05 | Do Hiep Q | Hollow Foam Beads for Treatment of Glioblastoma |
CA2768710A1 (en) * | 2009-07-24 | 2011-01-27 | Institut National De La Recherche Scientifique | Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies |
-
2012
- 2012-05-11 IT IT000814A patent/ITMI20120814A1/it unknown
-
2013
- 2013-05-10 EP EP13730352.5A patent/EP2846770B1/en active Active
- 2013-05-10 DK DK13730352.5T patent/DK2846770T3/en active
- 2013-05-10 WO PCT/IB2013/053792 patent/WO2013168131A1/en active Application Filing
- 2013-05-10 US US14/400,469 patent/US20150132397A1/en not_active Abandoned
- 2013-05-10 PT PT13730352T patent/PT2846770T/pt unknown
- 2013-05-10 PL PL13730352T patent/PL2846770T3/pl unknown
- 2013-05-10 CN CN201380032428.8A patent/CN104427975A/zh active Pending
- 2013-05-10 ES ES13730352.5T patent/ES2686561T3/es active Active
-
2014
- 2014-12-05 IN IN2475MUN2014 patent/IN2014MN02475A/en unknown
-
2016
- 2016-07-21 US US15/215,848 patent/US20160324770A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2013168131A1 (en) | 2013-11-14 |
ITMI20120814A1 (it) | 2013-11-12 |
US20160324770A1 (en) | 2016-11-10 |
US20150132397A1 (en) | 2015-05-14 |
IN2014MN02475A (pt) | 2015-07-10 |
ES2686561T3 (es) | 2018-10-18 |
DK2846770T3 (en) | 2018-09-17 |
PL2846770T3 (pl) | 2019-02-28 |
CN104427975A (zh) | 2015-03-18 |
EP2846770A1 (en) | 2015-03-18 |
EP2846770B1 (en) | 2018-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL238575A0 (en) | Systems and methods for administering drugs to the lung | |
EP3004083A4 (en) | COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | |
IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
EP2726141A4 (en) | DEVICE, SYSTEM AND METHODS FOR ORAL DELIVERY OF THERAPEUTIC COMPOUNDS | |
EP3038647A4 (en) | Combination therapy for the treatment of glioblastoma | |
HK1213794A1 (zh) | 聯合治療及用於治療脫髓鞘病症的用途 | |
HK1206937A1 (en) | Methods of administering pirfenidone therapy | |
EP2806926A4 (en) | SYSTEMS AND METHODS FOR DISPENSING RESPIRATORY THERAPY | |
EP3068353A4 (en) | Systems and methods for subretinal delivery of therapeutic agents | |
EP3010486A4 (en) | Chemical structures for localized delivery of therapeutic agents | |
EP2968739A4 (en) | Infusion systems for the controlled delivery of therapeutic agents | |
PT2846770T (pt) | Administração intratecal de inibidores de mtor para a terapia de doenças neurodegenerativas, neuroinflamatórias e neuro-oncológicas | |
EP2906583A4 (en) | PEPTIDES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
EP2974730A4 (en) | MEDICINES FOR RESPIRATORY DISEASES | |
HK1219224A1 (zh) | 角結膜病症的治療劑 | |
EP3103446A4 (en) | Pharmaceutical preparation for preventing and treating progressive myopia | |
ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
HK1218882A1 (zh) | 用於治療神經退化疾病和其它疾病的組合治療劑和方法 | |
EP3075380A4 (en) | Drug for treating vertebrae cervicales and lumber diseases | |
EP3049075A4 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
PT2922541T (pt) | Piridil-hidrazonas para o tratamento de tuberculose e doenças relacionadas | |
AU2012902640A0 (en) | Dosage Regime for Animal Treatment |